Abstract
Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Many experimental studies have shown that ketamine can induce cognitive impairments and schizophrenia-like symptoms. While much data have demonstrated that glial cells are associated with the pathophysiology of psychiatric disorders, including schizophrenia, the response of glial cells to ketamine and its significance to schizophrenia are not clear. The present study was intended to explore whether chronic ketamine treatment would induce behavioral and glial changes in mice. First, ketamine was used to stimulate behavioral abnormalities similar to schizophrenia evaluated by the open field test, elevated plus-maze test, Y maze test, novel object recognition test, and tail suspension test. Secondly, histopathology and Nissl staining were performed. Meanwhile, immunofluorescence was used to evaluate the expression levels of IBA-1 (a microglial marker) and GFAP (an astrocyte marker) in the mouse hippocampus for any change. Then, ELISA was used to analyze proinflammatory cytokine levels for any change. Our results showed that ketamine (25 mg/kg, i.p., qid, 12 days) induced anxiety, recognition deficits, and neuronal injury in the hippocampus. Moreover, chronic ketamine treatment enhanced GFAP expression in CA1 and DG regions of the hippocampus but did not influence the expression of IBA-1. Ketamine also increased the levels of IL-1β, IL-6, and TNF-α in the mouse hippocampus. Our study created a new procedure for ketamine administration, which successfully induce negative symptoms and cognitive-behavioral defects in schizophrenia by chronic ketamine. This study further revealed that an increase in astrocytosis, but not microglia, is associated with the mouse model of schizophrenia caused by ketamine. In summary, hippocampal astrocytes may be involved in the pathophysiology of ketamine-induced schizophrenia-like phenotypes through reactive transformation and regulation of neuroinflammation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdel-Salam OME, and El-Shamarka ME-S(2017) Nicorandil reverses the behavioral changes and brain oxidative stress in a model of schizophrenia induced by ketamine in mice. Comparative Clinical Pathology 26:955–963. https://doi.org/10.1007/s00580-017-2471-x
Adell A (2020) Brain NMDA receptors in schizophrenia and depression. Biomolecules 10:947. https://doi.org/10.3390/biom10060947
Ahmed HI, Abdel-Sattar SA, Zaky HS (2018) Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3beta/beta-catenin pathway. Naunyn Schmiedebergs Arch Pharmacol 391:1327–1338. https://doi.org/10.1007/s00210-018-1552-y
Arif M, Chikuma T, Ahmed MM, Yoshida S, Kato T (2007) Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801-treated rat brain regions. Neurosci Res 57:248–258. https://doi.org/10.1016/j.neures.2006.10.021
Balu DT (2016) The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv Pharmacol 76:351–382. https://doi.org/10.1016/bs.apha.2016.01.006
Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G (2003) Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:687–700. https://doi.org/10.1016/s0278-5846(03)00080-0
Ben-Azu B, Aderibigbe AO, Ajayi AM, Eneni AO, Omogbiya IA, Owoeye O, Umukoro S, Iwalewa EO (2019) Morin decreases cortical pyramidal neuron degeneration via inhibition of neuroinflammation in mouse model of schizophrenia. Int Immunopharmacol 70:338–353. https://doi.org/10.1016/j.intimp.2019.02.052
Bove M, Schiavone S, Tucci P, Sikora V, Dimonte S, Colia AL, Morgese MG, Trabace L (2022) Ketamine administration in early postnatal life as a tool for mimicking autism spectrum disorders core symptoms. Prog Neuropsychopharmacol Biol Psychiatry 117:110560. https://doi.org/10.1016/j.pnpbp.2022.110560
Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC (2018) NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology 142:41–62. https://doi.org/10.1016/j.neuropharm.2017.11.045
Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD (2012) The tail suspension test. J vis Exp 28:e3769. https://doi.org/10.3791/3769
Catts VS, Wong J, Fillman SG, Fung SJ, Shannon Weickert C (2014) Increased expression of astrocyte markers in schizophrenia: association with neuroinflammation. Aust N Z J Psychiatry 48:722–734. https://doi.org/10.1177/0004867414531078
Chan KW, Lee TM, Siu AM, Wong DP, Kam CM, Tsang SK, Chan CC (2013) Effects of chronic ketamine use on frontal and medial temporal cognition. Addict Behav 38:2128–2132. https://doi.org/10.1016/j.addbeh.2013.01.014
Chang CY, Luo DZ, Pei JC, Kuo MC Hsieh YC, Lai WS (2021) Not just a bystander: the emerging role of astrocytes and research tools in studying cognitive dysfunctions in schizophrenia. Int J Mol Sci 22:5343 https://doi.org/10.3390/ijms22105343
Chatterjee M, Ganguly S, Srivastava M, Palit G (2011) Effect of ‘chronic’ versus ‘acute’ ketamine administration and its ‘withdrawal’ effect on behavioural alterations in mice: implications for experimental psychosis. Behav Brain Res 216:247–254. https://doi.org/10.1016/j.bbr.2010.08.001
Chatterjee M, Jaiswal M, Palit G (2012) Comparative evaluation of forced swim test and tail suspension test as models of negative symptom of schizophrenia in rodents. ISRN Psychiatry 2012:595141. https://doi.org/10.5402/2012/595141
Chun H, Im H, Kang YJ, Kim Y, Shin JH, Won W, Lim J, Ju Y, Park YM, Kim S, Lee SE, Lee J, Woo J, Hwang Y, Cho H, Jo S, Park JH, Kim D, Kim DY, Seo JS, Gwag BJ, Kim YS, Park KD, Kaang BK, Cho H, Ryu H, Lee CJ (2020) Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H2O2(-) production. Nat Neurosci 23:1555–1566. https://doi.org/10.1038/s41593-020-00735-y
Ding R, Li Y, Du A, Yu H, He B, Shen R, Zhou J, Li L, Cui W, Zhang G, Lu Y, Wu X (2016) Changes in hippocampal AMPA receptors and cognitive impairments in chronic ketamine addiction models: another understanding of ketamine CNS toxicity. Sci Rep 6:38771. https://doi.org/10.1038/srep38771
Fan N, Luo Y, Xu K, Zhang M, Ke X, Huang X, Ding Y, Wang D, Ning Y, Deng X, He H (2015) Relationship of serum levels of TNF-alpha, IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers. Schizophr Res 169:10–15. https://doi.org/10.1016/j.schres.2015.11.006
Fan N, Xu K, Ning Y, Rosenheck R, Wang D, Ke X, Ding Y, Sun B, Zhou C, Deng X, Tang W, He H (2016) Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. Psychiatry Res 237:311–315. https://doi.org/10.1016/j.psychres.2016.01.023
Featherstone RE, Liang Y, Saunders JA, Tatard-Leitman VM, Ehrlichman RS, Siegel SJ (2012) Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiol Dis 47:338–346. https://doi.org/10.1016/j.nbd.2012.05.003
Feresten AH, Barakauskas V, Ypsilanti A, Barr AM, Beasley CL (2013) Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness. Schizophr Res 150:252–257. https://doi.org/10.1016/j.schres.2013.07.024
Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS (2013) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:206–214. https://doi.org/10.1038/mp.2012.110
Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB (2017) Review: Astrocytes in Alzheimer’s disease and other age-associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol 43:281–298. https://doi.org/10.1111/nan.12338
Gomes FV, Issy AC, Ferreira FR, Viveros MP, Bel Del EA, Guimaraes FS (2014) Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice Int J Neuropsychopharmacol 18 https://doi.org/10.1093/ijnp/pyu041
Gomes FV, Llorente R, Del Bel EA, Viveros MP, Lopez-Gallardo M, Guimaraes FS (2015) Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr Res 164:155–163. https://doi.org/10.1016/j.schres.2015.01.015
Graeber MB, Li W, Rodriguez ML (2011) Role of microglia in CNS inflammation. FEBS Lett 585:3798–3805. https://doi.org/10.1016/j.febslet.2011.08.033
Hallak JEC, Dursun SM, Bosi DC, de Macedo LRH, Machado-de-Sousa JP, Abrão J, Crippa JAS, McGuire P, Krystal JH, Baker GB, Zuardi AW (2011) The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 35:198–202. https://doi.org/10.1016/j.pnpbp.2010.11.002
Hoistad M, Heinsen H, Wicinski B, Schmitz C, Hof PR (2013) Stereological assessment of the dorsal anterior cingulate cortex in schizophrenia: absence of changes in neuronal and glial densities. Neuropathol Appl Neurobiol 39:348–361. https://doi.org/10.1111/j.1365-2990.2012.01296.x
Honey GD, Honey RA, O’Loughlin C, Sharar SR, Kumaran D, Suckling J, Menon DK, Sleator C, Bullmore ET, Fletcher PC (2005a) Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 15:749–759. https://doi.org/10.1093/cercor/bhh176
Honey GD, Honey RA, Sharar SR, Turner DC, Pomarol-Clotet E, Kumaran D, Simons JS, Hu X, Rugg MD, Bullmore ET, Fletcher PC (2005b) Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology 181:445–457. https://doi.org/10.1007/s00213-005-0001-z
Hou Y, Zhang H, Xie G, Cao X, Zhao Y, Liu Y, Mao Z, Yang J, Wu C (2013) Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice. Prog Neuropsychopharmacol Biol Psychiatry 45:107–116. https://doi.org/10.1016/j.pnpbp.2013.04.006
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308. https://doi.org/10.1176/ajp.148.10.1301
Jentsch JD Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–225. https://doi.org/10.1016/S0893-133x(98)00060-8
Jiang Y, Wang Y, Sun X, Lian B, Sun H, Wang G, Du Z, Li Q, Sun L (2017) Short- and long-term antidepressant effects of ketamine in a rat chronic unpredictable stress model. Brain Behav 7:e00749. https://doi.org/10.1002/brb3.749
Ke X, Ding Y, Xu K, He H, Wang D, Deng X, Zhang X, Zhou Y, Zhou C, Liu Y, Ning Y, Fan N (2018) The profile of cognitive impairments in chronic ketamine users. Psychiatry Res 266:124–131. https://doi.org/10.1016/j.psychres.2018.05.050
Khakh BS, Deneen B (2019) The emerging nature of astrocyte diversity. Annu Rev Neurosci 42:187–207. https://doi.org/10.1146/annurev-neuro-070918-050443
Khakpai F, Ebrahimi-Ghiri M, Alijanpour S, Zarrindast MR (2019) Ketamine-induced antidepressant like effects in mice: a possible involvement of cannabinoid system. Biomed Pharmacother 112:108717. https://doi.org/10.1016/j.biopha.2019.108717
Kim JW, Monteggia LM (2020) Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways. Behav Brain Res 380:112378. https://doi.org/10.1016/j.bbr.2019.112378
Kim R, Healey KL, Sepulveda-Orengo MT, Reissner KJ (2018) Astroglial correlates of neuropsychiatric disease: from astrocytopathy to astrogliosis. Prog Neuropsychopharmacol Biol Psychiatry 87:126–146. https://doi.org/10.1016/j.pnpbp.2017.10.002
Kozela E, Juknat A, Vogel Z (2017) Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid Int J Mol Sci 18:1669. https://doi.org/10.3390/ijms18081669
Kraeuter AK, Guest PC, Sarnyai Z (2019a) The elevated plus maze test for measuring anxiety-like behavior in rodents. Methods Mol Biol 1916:69–74. https://doi.org/10.1007/978-1-4939-8994-2_4
Kraeuter AK, Guest PC, Sarnyai Z (2019b) The open field test for measuring locomotor activity and anxiety-like behavior. Methods Mol Biol 1916:99–103. https://doi.org/10.1007/978-1-4939-8994-2_9
Kraeuter AK, Guest PC, Sarnyai Z (2019c) The Y-maze for assessment of spatial working and reference memory in mice. Methods Mol Biol 1916:105–111. https://doi.org/10.1007/978-1-4939-8994-2_10
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214. https://doi.org/10.1001/archpsyc.1994.03950030035004
Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455–467. https://doi.org/10.1016/S0893-133X(01)00243-3
Li CR, Zhang S, Hung CC, Chen CM, Duann JR, Lin CP, Lee TS (2017a) Depression in chronic ketamine users: sex differences and neural bases. Psychiatry Res Neuroimaging 269:1–8. https://doi.org/10.1016/j.pscychresns.2017.09.001
Li X, Guo C, Li Y, Li L, Wang Y, Zhang Y, Li Y, Chen Y, Liu W, Gao L(2017b) Ketamine administered pregnant rats impair learning and memory in offspring via the CREB pathway. Oncotarget 8:32433–32449. https://doi.org/10.18632/oncotarget.15405
Li Y, Shen R, Wen G, Ding R, Du A, Zhou J, Dong Z, Ren X, Yao H, Zhao R, Zhang G, Lu Y, Wu X (2017c) Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1beta, and TNF-alpha in the hippocampus of mice following acute or chronic administration. Front Pharmacol 8:139. https://doi.org/10.3389/fphar.2017.00139
Li Z, Boules M, Williams K, Gordillo A, Li S, Richelson E (2010) Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia. Neurobiol Dis 40:467–477. https://doi.org/10.1016/j.nbd.2010.07.011
Linnerbauer M, Wheeler MA, Quintana FJ (2020) Astrocyte crosstalk in CNS inflammation. Neuron 108:608–622. https://doi.org/10.1016/j.neuron.2020.08.012
Mei YY, Wu DC, Zhou N (2018) Astrocytic regulation of glutamate transmission in schizophrenia. Front Psychiatry 9:544. https://doi.org/10.3389/fpsyt.2018.00544
Monji A, Kato T, Kanba S (2009) Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63:257–265. https://doi.org/10.1111/j.1440-1819.2009.01945.x
Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, Yamauchi Y, Yamada S, Kanba S (2013) Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 42:115–121. https://doi.org/10.1016/j.pnpbp.2011.12.002
Morgan CJ, Curran HV, Committee IS, on D, (2012) Ketamine use: a review. Addiction 107:27–38. https://doi.org/10.1111/j.1360-0443.2011.03576.x
Morgan CJ, Muetzelfeldt L, Curran HV (2009) Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104:77–87. https://doi.org/10.1111/j.1360-0443.2008.02394.x
Morgan CJ, Riccelli M, Maitland CH, Curran HV (2004) Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend 75:301–308. https://doi.org/10.1016/j.drugalcdep.2004.03.006
Na K-S, Jung H-Y, Kim Y-K (2014) The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 48:277–286. https://doi.org/10.1016/j.pnpbp.2012.10.022
Nabeshima T, Mouri A, Murai R, Noda Y (2006) Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci 1086:160–168. https://doi.org/10.1196/annals.1377.003
Nikiforuk A, Holuj M, Kos T, Popik P (2016a) The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia. Neuropharmacology 105:351–360. https://doi.org/10.1016/j.neuropharm.2016.01.035
Nikiforuk A, Kos T, Holuj M, Potasiewicz A, Popik P (2016b) Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats. Neuropharmacology 101:389–400. https://doi.org/10.1016/j.neuropharm.2015.07.034
Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S (2010) Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry 67:155–166. https://doi.org/10.1001/archgenpsychiatry.2009.196
Pitsikas N, Carli M (2020) Ketamine disrupted storage but not retrieval of information in male rats and apomorphine counteracted its impairing effect. Neurosci Lett 737:135321. https://doi.org/10.1016/j.neulet.2020.135321
Radewicz K, Garey LJ, Gentleman SM, Reynolds R (2000) Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59:137–150. https://doi.org/10.1093/jnen/59.2.137
Reus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, Kapczinski F, Quevedo J (2015) The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300:141–154. https://doi.org/10.1016/j.neuroscience.2015.05.018
Näkki R, Nickolenko J, Chang J, Sagar SM, Sharp FR (1996) Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation. Experimental Neurology 137:234–241. https://dx.doi.org/10.1006/exnr.1996.0022
Schnieder TP, Dwork AJ (2011) Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry 69:134–139. https://doi.org/10.1016/j.biopsych.2010.08.027
Schousboe A, Waagepetersen HS (2005) Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox Res 8:221–225. https://doi.org/10.1007/BF03033975
Shang Y, Cheng J, Qi J, Miao H (2005) Scutellaria flavonoid reduced memory dysfunction and neuronal injury caused by permanent global ischemia in rats. Pharmacol Biochem Behav 82:67–73. https://doi.org/10.1016/j.pbb.2005.06.018
Sinner B, Graf BM (2008) Ketamine. Handb Exp Pharmacol 182:313–333. https://doi.org/10.1007/978-3-540-74806-9_15
Snijders G, van Zuiden W, Sneeboer MAM, Berdenis van Berlekom A, van der Geest AT, Schnieder T, MacIntyre DJ, Hol EM, Kahn RS, de Witte LD (2021) A loss of mature microglial markers without immune activation in schizophrenia. Glia 69:1251–1267. https://doi.org/10.1002/glia.23962
Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119:7–35. https://doi.org/10.1007/s00401-009-0619-8
Subhramanyam CS, Wang C, Hu Q, Dheen ST (2019) Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol 94:112–120. https://doi.org/10.1016/j.semcdb.2019.05.004
Tarasov VV, Svistunov AA, Chubarev VN, Sologova SS, Mukhortova P, Levushkin D, Somasundaram SG, Kirkland CE, Bachurin SO, Aliev G (2019) Alterations of astrocytes in the context of schizophrenic dementia. Front Pharmacol 10:1612. https://doi.org/10.3389/fphar.2019.01612
Trepanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP (2016) Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry 21:1009–1026. https://doi.org/10.1038/mp.2016.90
Trujillo KA, Smith ML, Sullivan B, Heller CY, Garcia C, Bates M (2011) The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders. ILAR J 52:366–378. https://doi.org/10.1093/ilar.52.3.366
Wang C, Aleksic B, Ozaki N (2015) Glia-related genes and their contribution to schizophrenia. Psychiatry Clin Neurosci 69:448–461. https://doi.org/10.1111/pcn.12290
Wang J, Zhou M, Wang X, Yang X, Wang M, Zhang C, Zhou S, Tang N (2014) Impact of ketamine on learning and memory function, neuronal apoptosis and its potential association with miR-214 and PTEN in adolescent rats. PLoS ONE 9:e99855. https://doi.org/10.1371/journal.pone.0099855
Wang Y, Xie L, Gao C, Zhai L, Zhang N, Guo L (2018) Astrocytes activation contributes to the antidepressant-like effect of ketamine but not scopolamine. Pharmacol Biochem Behav 170:1–8. https://doi.org/10.1016/j.pbb.2018.05.001
Wasik A, Bialon M, Zarnowska M, Antkiewicz-Michaluk L (2019) Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment. Pharmacol Biochem Behav 181:17–27. https://doi.org/10.1016/j.pbb.2019.04.002
Webster MJ, O’Grady J, Kleinman JE, Weickert CS (2005) Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133:453–461. https://doi.org/10.1016/j.neuroscience.2005.02.037
Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E (2005) Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 43:81–89
Williams M, Pearce RK, Hirsch SR, Ansorge O, Thom M, Maier M (2014) Fibrillary astrocytes are decreased in the subgenual cingulate in schizophrenia. Eur Arch Psychiatry Clin Neurosci 264:357–362. https://doi.org/10.1007/s00406-013-0482-4
Wu F, Ding J, Li HB, Miao HC, Bao R, Yang S (2019) Effects of electroacupuncture on expression of D1 receptor (D1R), phosphorylation of extracellular-regulated protein kinase 1/2 (p-ERK1/2), and c-Fos in the insular cortex of ketamine-addicted rats. Med Sci Monit Basic Res 25:26–32. https://doi.org/10.12659/MSMBR.913285
Yu W, Zhu H, Wang Y, Li G, Wang L, Li H (2015) Reactive transformation and increased BDNF signaling by hippocampal astrocytes in response to MK-801. PLoS ONE 10:e0145651. https://doi.org/10.1371/journal.pone.0145651
Yu X, Nagai J, Khakh BS (2020) Improved tools to study astrocytes. Nat Rev Neurosci 21:121–138. https://doi.org/10.1038/s41583-020-0264-8
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621–660. https://doi.org/10.1124/pr.117.015198
Zhang X, Zhao J, Chang T, Wang Q, Liu W, Gao L (2020) Ketamine exerts neurotoxic effects on the offspring of pregnant rats via the Wnt/beta-catenin pathway. Environ Sci Pollut Res Int 27:305–314. https://doi.org/10.1007/s11356-019-06753-z
Zuo D, Lin L, Liu Y, Wang C, Xu J, Sun F, Li L, Li Z, Wu Y (2016) Baicalin attenuates ketamine-induced neurotoxicity in the developing rats: involvement of PI3K/Akt and CREB/BDNF/Bcl-2 pathways. Neurotox Res 30:159–172. https://doi.org/10.1007/s12640-016-9611-y
Funding
This research is supported by the Natural Science Foundation of China (No. 82072111 and 82030057).
Author information
Authors and Affiliations
Contributions
Ying Wei: conceptualization, methodology, writing—original draft, writing—review and editing, formal analysis, investigation, resources, project administration. Li Xiao: methodology, writing—review and editing, investigation, visualization. Weihao Fan: validation, formal analysis, investigation, writing—original draft. Jing Zou: methodology, validation, data curation, visualization. Hong Yang: validation, formal analysis, investigation. Bo Liu: formal analysis, investigation. Yi Ye: conceptualization, methodology, writing—review and editing. Di Wen: conceptualization, methodology, writing—review and editing. Linchuan Liao: conceptualization, methodology, resources, writing—review and editing, supervision, project administration, funding acquisition.
Corresponding author
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wei, Y., Xiao, L., Fan, W. et al. Astrocyte Activation, but not Microglia, Is Associated with the Experimental Mouse Model of Schizophrenia Induced by Chronic Ketamine. J Mol Neurosci 72, 1902–1915 (2022). https://doi.org/10.1007/s12031-022-02046-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-022-02046-2